GO
Loading...

Idenix Pharmaceuticals Inc

More

  • 5 Stocks Under $10 Poised for Breakouts Thursday, 17 May 2012 | 12:50 PM ET

    Here’s a look at several under-$10 stocks that look poised to potentially trade higher from current levels.

  • Vertex Hopes Two Cystic Fibrosis Drugs Better Than One Tuesday, 24 Apr 2012 | 12:00 PM ET

    Vertex Pharmaceuticals is expected to report strong initial sales of its cystic fibrosis drug Kalydeco on Thursday as investors shift their attention away from the waning performance of the company's hepatitis C drug Incivek.

  • For Biotech, ‘Fail’ Is Making a Big Comeback Monday, 12 Mar 2012 | 3:00 PM ET
    Pharma Stocks

    After a hot streak, biotech stocks lose value as clinical trials fail.

  • Value Guru Surrounds News Corp., Jumps Into Biotech Wednesday, 15 Feb 2012 | 5:14 PM ET
    News Corp.'s headquarters in New York.

    Hedge funds that manage more than $100 million are required to disclose their equity holdings, options and convertible debt on a Form 13F. TheStreet.com examines Baupost Group's holdings.

  • Major Wave of Biotech Mergers Expected Thursday, 26 Jan 2012 | 2:48 PM ET

    Amgen and Celgene, looking to boost oncology offerings, announced separate deals for small biotech companies Thursday, the latest in what analysts expect to be a major wave of biotech mergers.

  • Which Biotech Company Is the Next Takeover Target? Monday, 9 Jan 2012 | 5:52 PM ET

    As the JPMorgan Health Care conference kicks off this week, one question remains for investors in the biotech space. What’s the next takeover target as large drug makers look to build out their pipeline?

  • 11 Biotech Stocks Hedge Funds Love and Hate Wednesday, 17 Aug 2011 | 12:02 PM ET

    Hedge funds peeled back the curtain this week to reveal a bit about what biotech stocks they were buying and selling during the second quarter.

  • Small-cap companies with an almost 400% return Thursday, 28 Aug 2008 | 9:53 AM ET

    So far this year, the Russell 2000 index of small-cap companies continues to outperform the Dow, and the S&P 500.  While most of these companies average only a $1 billion dollar market capitalization, some of their returns are proving resilient to an economic slowdown.